Topic: psoriatic arthritis
AbbVie is hoping two next-gen launches, Rinvoq and Skyrizi, can help pick up the slack from a declining Humira. New clinical data could aid the cause.
Johnson & Johnson is chasing giants in its play for psoriatic arthritis with Tremfya. Strong data could help the newcomer convince the FDA.
Besting AbbVie's megablockbuster Humira is no laughing matter, but now Eli Lilly's Taltz has doubled up on head-to-head wins.
Cosentyx has been battling it out with Taltz in psoriatic arthritis. But Lilly’s drug has a big win under its belt that Novartis can't tout.
AbbVie blockbuster-to-be Rinvoq only just hit the scene in rheumatoid arthritis, but it’s already on its way to a second indication.
Novartis’ Cosentyx is battling Lilly’s Taltz in three indications. Now, with new phase 3 data in spondyloarthritis, Novartis wants to make it four.
Looks like Amgen might not be buying Alexion after all. Instead, it’s beefing up in psoriasis, where it already sells blockbuster TNF inhibitor Enbrel.
To take on AbbVie’s megablockbuster Humira, drugmakers need compelling data for physicians. Could Eli Lilly's Taltz be up to the challenge?
After underwhelming sales in the first quarter, Eli Lilly’s Taltz is on the hot seat with analysts. Long-term clear skin data could build its case.